The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for subcutaneous (SC) maintenance dosing of lecanemab-irmb for the treatment of Alzheimer disease (AD) in ...
How Dementia Affects the Brain's Ability ... Machine Learning Reveals Behaviors Linked With Early Alzheimer's, Points to New Treatments Nov. 26, 2024 — Scientists used a new video-based machine ...